Last reviewed · How we verify
Desonide Cream
Desonide is a topical corticosteroid that reduces inflammation and suppresses immune responses in the skin by binding to glucocorticoid receptors.
Desonide is a topical corticosteroid that reduces inflammation and suppresses immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, dermatitis, psoriasis).
At a glance
| Generic name | Desonide Cream |
|---|---|
| Also known as | Desonide Cream 0.05% |
| Sponsor | NeoStrata Company, Inc. |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Desonide is a low-to-medium potency corticosteroid that works by activating glucocorticoid receptors in skin cells, leading to decreased production of inflammatory mediators and reduced immune cell infiltration. This results in decreased erythema, pruritus, and other inflammatory skin manifestations. It is applied topically and has minimal systemic absorption.
Approved indications
- Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, dermatitis, psoriasis)
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Local irritation or burning
- Folliculitis
Key clinical trials
- Alternation in the Human Microbiome With Commonly Used Topical Medications (PHASE1)
- 8-Week Atopic Dermatitis (AD) Treatment Study (PHASE3)
- Evaluation of the Vasoconstriction Properties of MC2-01 Cream (PHASE1)
- Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis (PHASE4)
- Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis (PHASE4)
- Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic Dermatitis (PHASE3)
- Photoaging Treatment With Imiquimod (NA)
- Efficacy Emollient on Xerosis in Children With Atopic Dermatitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Desonide Cream CI brief — competitive landscape report
- Desonide Cream updates RSS · CI watch RSS
- NeoStrata Company, Inc. portfolio CI